PCG
FATE icon

Private Capital Group’s Fate Therapeutics FATE Stock Holding History

Private Capital Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18
Closed -$1K – 1953
2022
Q1 		$1K Sell
18
-6
-25% -$232 ﹤0.01% 1930
2021
Q4 		$1K Buy
24
+12
+100% +$680 ﹤0.01% 1928
2021
Q3 		$1K Buy
+12
New +$941 ﹤0.01% 1983

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Private Capital Group's FATE Position: Q2 2022 in Review

Private Capital Group sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 18 shares — an estimated $1K sold.

Private Capital Group first reported a position in FATE in Q3 2021 and held it in 3 quarters. The position peaked at $1K in Q1 2022. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Private Capital Group reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Private Capital Group sold 18 Fate Therapeutics shares in Q2 2022, an estimated $1K.
  • Private Capital Group first reported a position in Fate Therapeutics in Q3 2021 and held it in 3 quarters.
  • Private Capital Group's Fate Therapeutics position peaked at $1K in Q1 2022.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.